Kymera Therapeutics, Inc. announced on April 9, 2025, the appointment of Noah Goodman, M.B.A., as Chief Business Officer. Mr. Goodman will be responsible for leading the company's business development strategy and activities.
Mr. Goodman brings nearly two decades of diverse experience in the life sciences industry to Kymera. His previous senior leadership roles include serving as President and Chief Business Officer at Chroma Medicine and nChroma Bio, and Executive Director and Head of Business Development at Cadent Therapeutics and Seres Therapeutics.
This appointment is intended to support Kymera's continued growth as it advances its expanding pipeline through clinical development and eventual commercialization. The company aims to build a fully integrated biopharmaceutical company focused on discovering and developing oral drugs with biologics-like activity.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.